Received: 21 December 2018
Accepted: 18 June 2019
First Online: 24 June 2019
Ethics approval and consent to participate
: The study had research permit from Finnish National Institute for Health and Welfare. The approval of ethics committee was not required because the research was based on hospital records and no patients were contacted.
: Not applicable.
: RO has received a grant from the Finnish Parkinson Foundation. The foundation has no role regarding study design, data collection, analysis, decision to publish and preparation of the manuscript. This does not alter our adherence to BMC Neurology policies on sharing data and materials. Other authors have declared that no competing interests regarding this study exist.RO has received travel support from Abbvie, Allergan and Zambon and participated in clinical trials by Portola Pharmaceuticals and Roche.FS is founder and CEO of NeuroInnovation Oy, has received consulting fees from Herantis Pharma, Orion Pharma, UCB, Renishaw, and LivaNova, lecture fees from Abbvie, UCB, Orion, and Zambon, and travel support from Abbvie, Herantis Pharma, Global Kinetics, UCB, NordicInfu Care, Zambon, and Medtronic, non-financial support from Abbott.EP has received consulting fees from NordicInfu Care, Abbvie, Herantis Pharma, Zambon, lecture fees from Abbott, Abbvie, Lundbeck, Medtronic, and Orion, and travel support from Abbott, Abbvie, Boston Scientific, Herantis Pharma, Medtronic.